Tigatuzumab clinical trials
Also written CS-1008.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses tigatuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 2
Daiichi Sankyo (6) · Ludwig Institute for Cancer Research (1) · University of Alabama at Birmingham (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tigatuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal CancerCompletedPhase 1Ludwig Institute for Cancer ResearchNCT01220999Written as CS-1008How we know
- Combination Chemotherapy With CS-1008 to Treat Ovarian CancerCompletedPhase 2Daiichi SankyoNCT00945191Written as CS-1008How we know
- Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic CancerCompletedPhase 2Daiichi SankyoNCT00521404Written as CS-1008 (humanized anti-DR5 antibody)How we know
- Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast CancerCompletedPhase 2University of Alabama at BirminghamNCT01307891Written as Abraxane + TigatuzumabHow we know
- Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other TreatmentsCompletedPhase 1Daiichi SankyoNCT01124630Written as CS-1008How we know
- CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)CompletedPhase 2Daiichi SankyoNCT00991796Written as CS-1008How we know
- CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With OxaliplatinTerminatedPhase 2Daiichi SankyoNCT00969033Written as CS-1008How we know
- Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)CompletedPhase 1Daiichi SankyoNCT00320827Written as CS-1008 (humanized anti-DR5 antibody)How we know
Given beside what is tested · 1 — tigatuzumab is usual care or a partner of the new treatment
Codes
What other systems call tigatuzumab · ClinicalTrials.gg INT005721
- MeSH (NLM) C552861tigatuzumabOne source NLM
- UNII (FDA) 237GB6IDKOTIGATUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3991247TigatuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62482TigatuzumabOne source FDA
- DrugBank DB15101One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C552861 | tigatuzumab | One source NLM |
| UNII (FDA) | 237GB6IDKO | TIGATUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3991247 | Tigatuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62482 | Tigatuzumab | One source FDA |
| DrugBank | DB15101 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.